gemtuzumab ozogamicin + arsenic trioxide

**gemtuzumab ozogamicin + arsenic trioxide** is a combination regimen involving two distinct anticancer agents, primarily investigated for use in **acute promyelocytic leukemia (APL)** and, more broadly, **acute myeloid leukemia (AML)**. - **Gemtuzumab ozogamicin** is an antibody-drug conjugate consisting of a humanized anti-CD33 monoclonal antibody linked to a cytotoxic agent (calicheamicin). It binds to CD33 on leukemic cells, is internalized, and releases calicheamicin to cause DNA double-strand breaks and apoptosis. - **Arsenic trioxide** is a small molecule antineoplastic agent that promotes partial differentiation and apoptosis in leukemic cells, particularly those with PML-RARA fusion proteins, through mechanisms such as proteasomal degradation and induction of oxidative stress. Combination therapy, especially with the addition of all-trans retinoic acid (ATRA), has been studied in high-risk or recurrent APL, improving event-free and overall survival, and may serve as a chemotherapy-free induction option for this subgroup[1][2][4][6]. **Gemtuzumab ozogamicin** is developed by Wyeth (now Pfizer), and **arsenic trioxide** by Teva and generic manufacturers.

Other names

GO + ATO